



Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

June 3, 2026

CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 on Wednesday, June 10, 2026, at 11:20 A.M. EDT.

The presentation will be webcast live and may be accessed [here](#) or by visiting Madrigal's Investor Relations Events and Presentations [page](#). A replay of the webcast will be available after the event.

About Madrigal

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdifra (resmetrom), is a once-daily, oral, liver-directed THR- β agonist designed to target key underlying causes of MASH. Rezdifra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdifra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com and follow us [on LinkedIn](#).

Investor Contact

Tina Ventura, IR@madrigalpharma.com

Media Contact

Christopher Frates, media@madrigalpharma.com

